GlycoNex Incorporation (TPEX:4168)

Market Cap	2.63B -0.2%
Revenue (ttm)	37.86M +157.5%
Net Income	-235.23M
EPS	-2.16
Shares Out	108.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	386,170
Average Volume	243,258
Open	24.30
Previous Close	23.45
Day's Range	23.60 - 24.50
52-Week Range	15.60 - 30.95
Beta	0.59
RSI	43.55
Earnings Date	Mar 13, 2026

About GlycoNex Incorporation

GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company’s development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under preclinical stage; GNX203, glycan-directed antibody drug currently under the lead optimization stage; and GNX1021, a first-in-class antibody–drug conjugate currently under preclinical stage. It is a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4168

Financial Performance

In 2025, GlycoNex Incorporation's revenue was 37.86 million, an increase of 157.54% compared to the previous year's 14.70 million. Losses were -235.23 million, 2.40% more than in 2024.